{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:44:24Z","timestamp":1760233464863,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dentistry Journal"],"abstract":"<jats:p>(1) Background: Multiple myeloma is a rare cancer that primarily affects the bone marrow. Osteoclasts are responsible for increased bone resorption and, therefore, bone destruction. Bisphosphonates are a class of drugs that can slow down bone resorption by reducing the number and action of osteoclasts. Intravenous injections of bisphosphonates (generally Zoledronic Acid) are administered to patients affected by Multiple Myeloma, but BRONJ is described as a serious side effect. This 5-year retrospective study aims to evaluate the efficacy of appropriate dental treatment protocols prior to initiating bisphosphonate therapy to prevent the development of BRONJ. (2) Methods: A total of 99 patients with symptomatic multiple myeloma were involved in this study (41\u201390 years, mean age 65 years, standard deviation 5 years). The data relating to the visits were tracked using a specific server and consulting the clinical reports. The AAOMS (American Association of Oral and Maxillofacial Surgeons) position was applied for both diagnosis and treatment. A total of 79 patients were examined before the administration of bisphosphonates (group A) and 20 after (group B). (3) Results: The entire sample required dental treatment: 23.2% underwent restorative therapy, 8% endodontic treatments, 44.4% tooth extractions. Periodontal disease was present in 41.4% of the patients. No osteonecrosis was observed in the first group, whereas BRONJ was found in five patients of the second one (25%) and two patients (10%) showed osteosclerotic areas under investigation [OR 0.026 (CI 0.0027 to 0.2454)]. (4) Conclusions: In the literature, there are no precise data about the prevalence of BRONJ. Despite the limitation of the present study, we point out that dental treatment before the treatment with intravenous bisphosphonates can help in reducing the incidence of BRONJ and good dental status is necessary for BRONJ prevention.<\/jats:p>","DOI":"10.3390\/dj9020011","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T12:16:18Z","timestamp":1611144978000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-6227","authenticated-orcid":false,"given":"Christian","family":"Bacci","sequence":"first","affiliation":[{"name":"Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Cerrato","sequence":"additional","affiliation":[{"name":"Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Dotto","sequence":"additional","affiliation":[{"name":"Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Baril\u00e0","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albana","family":"Li\u00e7o","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Stellini","sequence":"additional","affiliation":[{"name":"Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-1017","authenticated-orcid":false,"given":"Gastone","family":"Zanette","sequence":"additional","affiliation":[{"name":"Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","article-title":"Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Rajkumar","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00005537-199706000-00007","article-title":"Head and neck manifestations of plasma cell neoplasms","volume":"107","author":"Nofsinger","year":"1997","journal-title":"Laryngoscope"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/adpa.2002.33458","article-title":"Plasma cell dyscrasias and the head and neck","volume":"6","author":"Batsakis","year":"2002","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_4","unstructured":"(2016, February 25). Available online: http:\/\/www.airc.it\/tumori\/mieloma-multiplo.asp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in mul-tiple myeloma: Recommendations of an expert panel on behalf of the Eu-ropean Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_7","unstructured":"Neville, B.W., Damm, D.D., Allen, C.M., and Bouquot, J.E. (2009). Hematologic disorders. Oral and Maxillofacial Pathology, Saunders-Elsevier. [3rd ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.4049\/jimmunol.138.5.1464","article-title":"Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption","volume":"138","author":"Stashenko","year":"1987","journal-title":"J. Immunol."},{"key":"ref_9","first-page":"6743","article-title":"A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma","volume":"8","author":"Xiaoxue","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_10","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: A network meta-analysis (Review)","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Libr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple (MRC Myeloma IX): A randomized controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","article-title":"The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future","volume":"16","author":"Pozzi","year":"2011","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cerrato, A., Zanette, G., Boccuto, M., Angelini, A., Valente, M., and Bacci, C. (2020). Actinomyces and MRONJ: A retrospective study and a literature review. J. Stomatol. Oral Maxillofac. Surg., in press.","DOI":"10.1016\/j.jormas.2020.07.012"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteo- necrosis of the jaw: So many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.joms.2009.01.005","article-title":"Epidemiology of bisphosphonate-related osteonecrosis of the jaws: The utility of a national registry","volume":"67","author":"Gliklich","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_17","first-page":"3917","article-title":"Incidence of Bisphosphonate-related Osteonecrosis of the Jaw in Consideration of Primary Diseases and Concomitant Therapies","volume":"33","author":"Assaf","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1200\/JCO.2011.35.1551","article-title":"Osteonecrosis of the Jaw After Zoledronic Acid and Denosumab Treatment","volume":"29","author":"Fusco","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.joms.2009.08.005","article-title":"Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma","volume":"68","author":"Bernardeschi","year":"2010","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_26","first-page":"3613","article-title":"Antibiotic prophylaxis before dental procedures can reduce ONJ incidence","volume":"110","author":"Montefusco","year":"2007","journal-title":"ASH Annu. Meet. Abstr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-051X.2005.00799.x","article-title":"Analytical epidemiology of periodontitis","volume":"32","author":"Borrell","year":"2005","journal-title":"J. Clin. Periodontol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J. Clin. Periodontol."},{"key":"ref_29","first-page":"2684924","article-title":"The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention","volume":"2018","author":"Panzarella","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: Updated reccomendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw in cancer patients","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_31","first-page":"e6944","article-title":"Medication-related Osteonecrosis of the Jaw: A review","volume":"12","author":"Aldhalaan","year":"2020","journal-title":"Cureus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00520-013-1960-y","article-title":"The multiple oral presentations of multiple myeloma","volume":"22","author":"Cardoso","year":"2014","journal-title":"Supportive Care Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors","volume":"24","author":"Badros","year":"2006","journal-title":"J. Clin. Oncol."}],"container-title":["Dentistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2304-6767\/9\/2\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:13:11Z","timestamp":1760159591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2304-6767\/9\/2\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["dj9020011"],"URL":"https:\/\/doi.org\/10.3390\/dj9020011","relation":{},"ISSN":["2304-6767"],"issn-type":[{"type":"electronic","value":"2304-6767"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}